Opinion|Videos|March 24, 2025
Current Treatment Landscape for Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.
Advertisement
Video content above is prompted by the following:
- What is the current treatment landscape for patients who have late-line RRMM?
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC
2
The Emotional Side of Cancer Care Beyond Medical Treatment
3
Besremi Recognized by Updated Guidelines for Essential Thrombocythemia
4
Beyond Statistics: Lessons in Mindset and Action from a Cancer Survivor
5